Comparative Pharmacology
Head-to-head clinical analysis: PEDIAMYCIN 400 versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEDIAMYCIN 400 versus PROKLAR.
PEDIAMYCIN 400 vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
400 mg orally every 6 hours for 10 days.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic